← 返回

在初治 CRC 患者中,肿瘤浸润 NK 和 NKT 细胞上 PD-1 及其他免疫检查点的表达与更长的无病生存期相关

英文原题:PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients.

查看英文原题

PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients.

PubMed 2022/11/27(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

多种变量,如微卫星不稳定性或炎症介质,在结直肠癌(CRC)的发生和进展中起关键作用。自然杀伤(NK)细胞和自然杀伤T(NKT)细胞参与CRC的预后。肿瘤微环境(TME)的免疫组分影响癌症进展和治疗反应。我们报告,肿瘤浸润PD-1 + NK和NKT细胞频率较高的CRC患者,其无病生存期(DFS)显著长于频率较低的患者。与此一致,肿瘤浸润PD-1 - NK和NKT细胞频率较高的患者显示较短的DFS。肿瘤浸润PD-1 + TIM-3 +、PD-1 + TIGIT +、PD-1 + ICOS +、PD-1 + LAG-3 + NK细胞,以及PD-1 + TIM-3 +、PD-1 + TIGIT + 和PD-1 + LAG-3 + NKT细胞与DFS之间无显著关联。本研究强调了肿瘤浸润NK和NKT细胞上PD-1表达的重要性及其与CRC患者疾病预后的关联。

展开英文摘要原文

A variety of variables, such as microsatellite instability or inflammatory mediators, are critical players in the development and progression of colorectal cancer (CRC). Natural killer (NK) and natural killer T (NKT) cells are involved in the prognoses of CRC. Immunological components of the tumor microenvironment (TME) impact cancer progression and therapeutic responses.

We report that CRC patients with higher frequencies of tumor-infiltrating PD-1 + NK and NKT cells had significantly longer disease-free survival (DFS) than patients with lower frequencies. In agreement with that, patients with higher frequencies of tumor-infiltrating PD-1 - NK and NKT cells showed shorter DFS. There were no significant associations between tumor-infiltrating PD-1 + TIM-3 + , PD-1 + TIGIT + , PD-1 + ICOS + , PD-1 + LAG-3 + NK cells, and PD-1 + TIM-3 + , PD-1 + TIGIT + , and PD-1 + LAG-3 + NKT cells with DFS.

This study highlights the significance of PD-1 expression on tumor-infiltrating NK and NKT cells and its association with disease prognoses in CRC patients.

论文信息

作者
Al-Mterin MA、Murshed K、Elkord E
第一作者单位
Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, 616, Nizwa, Oman.Oman
通讯作者单位
Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, 616, Nizwa, Oman. e.elkord@salford.ac.uk.Oman
期刊
Cancer immunology, immunotherapy : CII2023 Jun
原文标识
PubMed 36436018 · DOI 10.1007/s00262-022-03337-8